...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice
【24h】

Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice

机译:用敏感的LC-MS / MS法同时测定小鼠血浆中的帕氏氧化物及其主要代谢物Valdecoxib和羟基化Valdecoxib,以阐明肿瘤轴承小鼠的药物代谢降低

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Parecoxib (PX), a prodrug of valdecoxib (VX), is an injectable selective COX-2 inhibitor, and is recommended for the treatment of cancer pain. PX can be rapidly hydrolyzed into its active metabolite VX, and VX is further metabolized into hydroxylated valdecoxib (OH-VX) by cytochrome P450 enzymes. However, cancer patients have been reported to possess reduced drug metabolism ability, which might cause excessive drug accumulation Such overdose of PX significantly increased the risk of renal safety and cardiovascular events. Therefore, it is necessary to elucidate the concentration profiles of PX and its metabolites in cancer status. In this study, a sensitive, rapid and specific LC-MS/MS method for quantification of PX, VX and OH-VX in the plasma of tumor bearing mouse was developed and validated. After protein precipitation, all the analytes were separated on an Agilent ZORBAX Extend-C18 HPLC column (2.1 x 100 mm, 3.5 mu m)with gradient elution. The analytes were detected by an electrospray negative ionization mass spectrometry in the multiple reaction monitoring mode. The transition m/z 369.0/ar=r/ 119.0,m/z 312.9/ar=r/ 117.9, m/z 329.0/ar=r/ 196.0, and m/z 307.1/ar=r/ 161.3 were used for monitoring PX, VX, OH-VX and IS respectively. The calibration curves of the analytes showed good linearity over the concentration range of3-3000 ng/mL for PX and VX, and 3-1000 ng/mL for OH-VX. Intra- and inter-batch accuracies (in terms of relative error, RE 9.9%) and precisions (in terms of relative standard deviation, RSD 8.8%) satisfied the standard of validation. The matrix effect, recovery and stability were also within acceptable criteria. The method was successfully applied to the pharmacokinetics study of PX in tumor bearing mice, and PX and VX levels were found elevated with the growth of tumor volume, which might increase the risk of drug overdose. (C) 2018 Elsevier B.V. All rights reserved.
机译:Parecoxib(PX)是Valdecoxib(Vx)的前药,是可注射选择性Cox-2抑制剂,并建议治疗癌症疼痛。 PX可以快速水解成其活性代谢物Vx,并且通过细胞色素P450酶进一步代谢到羟基化的Valdecoxib(OH-Vx)中。然而,据报道,癌症患者药物代谢能力降低,这可能导致过量的药物积累这种过量的PX显着增加了肾脏安全和心血管事件的风险。因此,有必要阐明PX的浓度谱及其在癌症地位中的代谢物。在该研究中,开发并验证了肿瘤轴承小鼠血浆中Px,Vx和OH-Vx的敏感,快速和特异性LC-MS / MS方法。在蛋白质沉淀后,用梯度洗脱在安置Zorbax延伸-C18 HPLC柱(2.1×100mm,3.5μm)上分离所有分析物。通过电喷雾负电离质谱法在多反应监测模式中检测分析物。过渡M / z 369.0 / Ar = r / 119.0,m / z 312.9 / ar = r / 117.9,m / z 329.0 / ar = r / 196.0和m / z 307.1 / ar = r / 161.3用于监测PX,Vx,OH-VX和是。分析物的校准曲线显示出PX和Vx的3-3000ng / ml浓度范围内的良好线性,以及用于OH-Vx的3-1000ng / ml。批次间和间歇性的精度(根据相对误差,RE <9.9%)和精确(在相对标准偏差方面,RSD <8.8%)满足验证标准。基质效应,回收和稳定性也在可接受的标准中。该方法成功地应用于肿瘤轴承小鼠PX的药代动力学研究,发现PX和VX水平随着肿瘤体积的生长而升高,这可能会增加药物过量的风险。 (c)2018年elestvier b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号